Efficacy, safety, and PD-L1–defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis
Chang Ma, Hoon Koon Teoh, Delai Qiu, Yingnan Zhang, Shubao Yang, Yang Zhao, Chen Zhao, Hooi Tin Ong · 2026
Read Efficacy, safety, and PD-L1–defined outcomes of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis by Chang Ma, Hoon Koon Teoh, Delai Qiu, Yingnan Zhang, Shubao Yang, Yang Zhao, Chen Zhao, Hooi Tin Ong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13506814.txt.
Description
A peer-reviewed research article from Europe PMC (2026). BackgroundNeoadjuvant immune checkpoint inhibitors combined with chemotherapy improve pathological complete response in early-stage triple-negative breast cancer, but the consistency of benefit, role of PD-L1 expression, and immune-related toxicity remain clinically relevant.MethodsPubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to June 30, 2026, for randomized trials comparing neoadjuvant immune checkpoint inhibitors plus chemotherapy with chemotherapy alone or placebo plus chemotherapy in early-stage triple-negative breast cancer. The primary efficacy analysis was restricted to phase III trials.
Catalog record
| CREATOR | Chang Ma, Hoon Koon Teoh, Delai Qiu, Yingnan Zhang, Shubao Yang, Yang Zhao, Chen Zhao, Hooi Tin Ong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |